317 related articles for article (PubMed ID: 15556771)
1. Design, synthesis, and inhibition of platelet aggregation for some 1-o-chlorophenyl-1,2,3,4-tetrahydroisoquinoline derivatives.
Yang J; Hua WY; Wang FX; Wang ZY; Wang X
Bioorg Med Chem; 2004 Dec; 12(24):6547-57. PubMed ID: 15556771
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
Storey RF; Wilcox RG; Heptinstall S
Platelets; 2002 Nov; 13(7):407-13. PubMed ID: 12487788
[TBL] [Abstract][Full Text] [Related]
3. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
4. P2Y12, a new platelet ADP receptor, target of clopidogrel.
Herbert JM; Savi P
Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
[TBL] [Abstract][Full Text] [Related]
5. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Steinhubl S; Roe MT
Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
[TBL] [Abstract][Full Text] [Related]
6. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
7. Identification and biological activity of the active metabolite of clopidogrel.
Savi P; Pereillo JM; Uzabiaga MF; Combalbert J; Picard C; Maffrand JP; Pascal M; Herbert JM
Thromb Haemost; 2000 Nov; 84(5):891-6. PubMed ID: 11127873
[TBL] [Abstract][Full Text] [Related]
8. Deaggregation is an integral component of the response of platelets to ADP in vitro: kinetic studies of literature and original data.
Maayani S; Tagliente TM; Schwarz T; Craddock-Royal B; Alcala C; Marrero G; Martinez R
Platelets; 2001 Aug; 12(5):279-91. PubMed ID: 11487380
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
[TBL] [Abstract][Full Text] [Related]
10. P2Y receptor antagonists in thrombosis.
Boeynaems JM; van Giezen H; Savi P; Herbert JM
Curr Opin Investig Drugs; 2005 Mar; 6(3):275-82. PubMed ID: 15816504
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.
Behan MW; Fox SC; Heptinstall S; Storey RF
Platelets; 2005 Mar; 16(2):73-80. PubMed ID: 15823862
[TBL] [Abstract][Full Text] [Related]
12. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
[TBL] [Abstract][Full Text] [Related]
13. Construction of drug screening cell model and application to new compounds inhibiting FITC-fibrinogen binding to CHO cells expressing human alphaIIbbeta3.
Yang J; Yao J; Chen J; Wang XN; Zhu TY; Chen LL; Chu P
Eur J Pharmacol; 2009 Sep; 618(1-3):1-8. PubMed ID: 19619528
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of N6-alkyl(aryl)-2-alkyl(aryl)thioadenosines as antiplatelet agents.
Liu G; Xu J; Chen N; Zhang S; Ding Z; Du H
Eur J Med Chem; 2012 Jul; 53():114-23. PubMed ID: 22531380
[TBL] [Abstract][Full Text] [Related]
15. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients.
Gurbel PA; Bliden KP; Etherington A; Tantry US
Thromb Res; 2007; 121(1):107-15. PubMed ID: 17400283
[TBL] [Abstract][Full Text] [Related]
16. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
[TBL] [Abstract][Full Text] [Related]
17. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Storey RF; Husted S; Harrington RA; Heptinstall S; Wilcox RG; Peters G; Wickens M; Emanuelsson H; Gurbel P; Grande P; Cannon CP
J Am Coll Cardiol; 2007 Nov; 50(19):1852-6. PubMed ID: 17980251
[TBL] [Abstract][Full Text] [Related]
19. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective.
Packham MA; Mustard JF
Semin Thromb Hemost; 2005 Apr; 31(2):129-38. PubMed ID: 15852216
[TBL] [Abstract][Full Text] [Related]
20. Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding.
Singh J; Zeller W; Zhou N; Hategen G; Mishra R; Polozov A; Yu P; Onua E; Zhang J; Zembower D; Kiselyov A; Ramírez JL; Sigthorsson G; Bjornsson JM; Thorsteinsdottir M; Andrésson T; Bjarnadottir M; Magnusson O; Fabre JE; Stefansson K; Gurney ME
ACS Chem Biol; 2009 Feb; 4(2):115-26. PubMed ID: 19193156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
